One-pot CRISPR diagnostics for the rapid detection of Candida species and antimicrobial resistance biomarkers
- 1University of Toronto
Abstract
Antimicrobial resistance (AMR) is a growing public health threat, where drug-resistant Candida infections are associated with increased hospital costs, lengths of stay, and high mortality rates. Current diagnostic methods are slow and labor-intensive, causing delays in diagnosis and patient treatment. In this research, we propose a rapid CRISPR-based diagnostic for identifying Candida pathogens and antifungal resistance biomarkers in clinical applications. One-pot CRISPR assay designs are optimized for three clinically relevant Candida species, achieving attomolar sensitivity with synthetic DNA and validating performance on cultured isolates. Strategies are developed to engineer CRISPR gRNA to control one-pot reaction kinetics, enhancing discrimination of single nucleotide polymorphism (SNP) resistance mutations associated with azole and echinocandin antifungals. This research expands our understanding of the design of one-pot CRISPR reactions for sensitive detection of DNA, while establishing a foundation for faster, more precise AMR diagnostics to improve surveillance and outbreak management of fungal infections.
Related
- Artificial Intelligence in Rapid Diagnostics for Antimicrobial Resistance: From Bench to Bedside
- Azithromycin in crisis: antimicrobial resistance, diagnostics gaps, and vaccine-linked stewardship for enteric infections in low- and middle-income countries
- Cross-kingdom antimicrobial resistance profiling: A unified multiplex PCR assay for simultaneous bacterial and fungal detection
- Concordance of next-generation sequencing and conventional microbiology for pathogen detection and antimicrobial resistance prediction in pneumonia
- Genome architecture drives antifungal resistance in Candida auris
BibTeX
@misc{heathcote2026onepot,
title = {{One-pot CRISPR diagnostics for the rapid detection of Candida species and antimicrobial resistance biomarkers}},
author = {A. Heathcote and M. Bird and H. Jeong and X. Li and R. Kozak and N. E. Weckman},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.01.26361059},
url = {https://www.medrxiv.org/content/10.64898/2026.09.01.26361059v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - One-pot CRISPR diagnostics for the rapid detection of Candida species and antimicrobial resistance biomarkers
AU - A. Heathcote
AU - M. Bird
AU - H. Jeong
AU - X. Li
AU - R. Kozak
AU - N. E. Weckman
PY - 2026
DA - 2026/09/01
PB - medRxiv
DO - 10.64898/2026.09.01.26361059
UR - https://www.medrxiv.org/content/10.64898/2026.09.01.26361059v1
AB - Antimicrobial resistance (AMR) is a growing public health threat, where drug-resistant Candida infections are associated with increased hospital costs, lengths of stay, and high mortality rates. Current diagnostic methods are slow and labor-intensive, causing delays in diagnosis and patient treatment. In this research, we propose a rapid CRISPR-based diagnostic for identifying Candida pathogens and antifungal resistance biomarkers in clinical applications. One-pot CRISPR assay designs are optimized for three clinically relevant Candida species, achieving attomolar sensitivity with synthetic DNA and validating performance on cultured isolates. Strategies are developed to engineer CRISPR gRNA to control one-pot reaction kinetics, enhancing discrimination of single nucleotide polymorphism (SNP) resistance mutations associated with azole and echinocandin antifungals. This research expands our understanding of the design of one-pot CRISPR reactions for sensitive detection of DNA, while establishing a foundation for faster, more precise AMR diagnostics to improve surveillance and outbreak management of fungal infections.
ER -